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Poly(ADP-ribose) polymerases (PARPs) comprise of a large family of 17 proteins encoded by various genes which
participate in genome maintenance, apoptosis, inflammatory responses and the regulation of gene expression
programs. PARP inhibitors, as therapeutic agents, come into play acting on both PARP 1 and PARP 2. These drugs
seem to target tumor cells in a moment of vulnerability when they are undergoing DNA repair. In the past few
years this class of anti-cancer drug has been discovered to show a promising niche in the clinic.Letter to the Editor
Poly(ADP-ribose) polymerases (PARPs, aka diphtheria
toxin-like ADP-ribosyltransferases [ARTDs]) comprise
of a large family of 17 proteins encoded by various genes
which participate in genome maintenance, apoptosis, in-
flammatory responses and the regulation of gene expres-
sion programs [1,2]. Out of these 17 proteins, PARP1
and PARP2 are the only enzymes whose catalytic activity
is turned on when there is a single strand break (SSB) in
the DNA [3].
PARPs constitutes of four functional domains: a DNA-
binding domain, a B domain, an auto-modification do-
main and a catalytic domain. The DNA binding domain
comprises of two zinc fingers and is involved in de-
tecting and resealing DNA breaks [4]. In addition to
containing a site which is acted upon by caspases result-
ing in inactivation of PARP, domain B also has a bipart-
ite nuclear localization signal which is involved in the
nuclear homing of PARP1 [5]. The automodification
domain has a BRCT motif and is responsible for letting
go of the protein from DNA after the catalytic reaction
has occurred at the catalytic domain. The catalytic
domain is involved in the synthesis of the poly (ADP-
ribose) chain.
Following DNA damage, PARP binds to nicotinamide
adenine dinucleotide and splits it off at the nicotina-
mide–ribose bond with polymerization of the ADP-
ribose moiety [6]. Repetition of this step results in the* Correspondence: asfandyarsheikh@gmail.com
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reproduction in any medium, provided the orsynthesis of a multi-branched polymer of ADP-ribose on
either nuclear protein acceptors located on chromatin
or on the PARP itself [7]. These automodification and
heteromodification reactions ensure the longevity of
damaged replicating cells because the poly (ADP-ribose)
chain attracts the attention of DNA repairing enzymes
and scaffolding proteins such as DNA ligase III, DNA
polymerase beta and X-ray cross-complementing gene 1
which in turn take part in a process called base excision
repair (BER) [8].
Two theories have been proposed by which PARP
is thought to induce apoptosis in cells. First, there is
the caspase independent pathway in which PARP is ex-
cessively stimulated, and the other is the caspase
dependent pathway in which PARP is inactivated. In the
first pathway, it is believed that PARP1 activation and
the subsequent synthesis of PAR polymer serves as a
cell death signal which leads to the release of apoptosis-
inducing factor (AIF) from the mitochondria into the
nucleus [9]. AIF then initiates apoptosis. However, in
the other pathway, PARP is rapidly and specifically
cleaved by caspase-3, a mammalian ICE-related prote-
ase. It is believed that PARP cleavage ensures that all
cells undergoing self-destruction turn off protective
mechanisms like DNA repair associated with PARP ac-
tivity [10]. The exact mechanism of these two processes
and the intermediate steps involved are not fully
understood.
Even without complete apprehension of the mecha-
nisms of the Poly(ADP-ribose) polymerases, there has
been significant research towards targeting these pro-
teins in cancer patients. This is where the class of PARPl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.infectagentscancer.com/content/8/1/46inhibitors as therapeutic agents come into play acting on
both PARP 1 and PARP 2. These drugs seem to target
tumor cells in a moment of vulnerability when they are
undergoing DNA repair [11].
Early clinical phase 1 trials were conducted on breast,
ovarian and prostate cancer targeting the BRCA1/2
muations. The rationale for use of PARP inhibitors in
these cancers represent an exquisite example of how
different pathways cooperate to repair damage [12,13].
BRCA1 and BRCA2 have an essential role in DNA
double-strand break repair via homologous recombin-
ation, whereas PARP, as mentioned earlier, has a role in
BER. It has been shown that BRCA1 or BRCA2 dysfunc-
tion sensitizes cells to the PARP inhibition, which sub-
sequently results in chromosomal instability and cell
cycle arrest and apoptosis, thereby working syner-
gistically and providing a novel therapeutic option with-
out the need for an exogenous DNA-damaging agent
[12,13].
Iniparib (BSI 201) being one of the initial candidates
showed serious potential but failed to meet expectations
in phase III trails and was eventually disproved as a
PARP inhibitor [1]. Olaparib (AZD2281), another PARP
inhibitor, produced positive anti-tumor results in cancer
patients with BRCA1/2 mutations [14]. Currently there
are 8 molecules in clinical trials which follow two distinct
pathways of pharmacodynamics. The first is a monother-
apy which targets tumor cells that have a defect in the
DNA repair mechanisms. The second is a combination
therapy with DNA damaging chemotherapeutic treat-
ments thus offering a potentiating effect to cause the cell
to undergo apoptosis [1]. Patients evaluated in clinical tri-
als with germline BRCA1/2 mutations, through one of
those pathways, have seen a 40% response rate with
olaparib in platinum sensitive ovarian cancer [15]. PARPis
have also been proven to be the first treatment for
BRCA1/2 mutation carrier in prostate cancer patients and
have promising anti-tumor activity [16].
It is important to know that BRCA1/2 associated can-
cers are quite rare and only account for less than 5% of
breast-cancer patients so it is crucial to see how PARPis
function on other cancers. An interesting match is
triple negative breast cancer in which tumors lack
expression of the estrogen receptor (ER), progesterone
receptor (PR), and human epidermal growth factor
receptor 2 (HER2) [11]. In a trial conducted by
O’Shaughnessy, triple negative breast cancer patients
were given iniparib in conjunction with gemcitabine
and carboplatin (chemotherapy doublet) which im-
proved the rate of clinical benefit from 34% to 56%
(P = 0.01) and the rate of overall response from 32% to
52% (P = 0.02) [17]. Unfortunately despite recent
advances in the clinical evaluation of various PARP
inhibitors in triple-negative breast cancer (TNBC)patients, there has been very little anti-tumor progres-
sion beyond PARPis [18]. Another example is a trial
conducted with rucaparib (PF-01367338, AG014699) in
combination with temozolomide for the treatment of
metastatic melanoma which showed positive signs of
chemopotentiation. Results showed that response rate
was 17.4%, median time to progression 3.5 months, me-
dian overall survival was 9.9 months, and 36% of pa-
tients were progression-free at 6 months [19].
Since PARP inhibitors are blocking the pathway to re-
pair damaged DNA; they require a selective increase in
DNA damage to tumor cells compared to normal cells
in order to produce an enhanced therapeutic effect by
chemotherapy. Thus it would be beneficial if the tumor
cells already harbored DNA repair defects such as the
case with BRCA1/2 mutations. By blocking both DNA
damage repair (DDR) pathways, the first being a tumor
germline defect in a non-BER pathway and the second
being a PARP inhibited BER pathway, it decreases the
chances of the tumor cells to withstand DNA damage.
This phenomenon is termed ‘synthetic lethality’ and is
very effective in preventing the tumor cells from repli-
cating efficiently. This theory could also be applied to
include treatment of tumors with defects in other HR
pathway proteins such as PTEN-deficient cells which
are sensitive to PARP inhibitors probably due to the in-
volvement in the expression of RAD51, another gene
encoding for DNA double strand break repairs [15].
One thing to note is the limitations of PARP inhibitors
with regards to ‘PARP trapping’ which occurs during
PARP inhibitor treatments. In normal cells the PARP1/2
bind to DNA and then recruit other proteins to do the
repairing after which the PARPs are released off the
DNA. But the inhibitors trap the PARP in the PARP-
DNA complex which makes a lethal PARP poison, so to
speak. This phenomenon is more detrimental to the cell
than the DNA breaks that occur during normal cell rep-
lication. Thus PARP inhibitors should be classified not
only in their enzyme inhibition abilities but also accord-
ing to their potency to trap PARP [20].
In the past few years this class of anti-cancer drug
has been discovered to show a promising niche in the
clinic. There are some limitations including resistance
but that is to be expected with cancer cells [21]. But the
amount of research being poured into this exciting new
class of anti-tumor therapeutics is bound to produce
interesting results. Current researchers should be
asking the questions related to development of PARP
inhibitors that will enhance DNA damage in tumor
cells that lack an intrinsic defect in DDR thus being
able to divert the synthetic lethality condition [15].
Hopefully with some answers there will be an improved
therapy for patients with cancers that have previously
been lacking in treatments.
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